BIOCRYST PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 536
- Market Cap
- $1.7B
- Website
- http://www.biocryst.com
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
- Conditions
- First Posted Date
- 2007-07-16
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 144
- Registration Number
- NCT00501735
- Locations
- 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇫🇷Creteil, Creteil, France
🇫🇷Hopital Hotel-Dieu, Clermont-Ferrand, France
Intramuscular Peramivir for the Treatment of Uncomplicated Influenza
- Conditions
- First Posted Date
- 2007-06-15
- Last Posted Date
- 2008-01-30
- Lead Sponsor
- BioCryst Pharmaceuticals
- Registration Number
- NCT00486980
Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza
- Conditions
- Interventions
- First Posted Date
- 2007-03-29
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 137
- Registration Number
- NCT00453999
- Locations
- 🇺🇸
Pulmonary Associates of Mobile, P.C., Mobile, Alabama, United States
🇺🇸Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2012-01-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT00419081
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸New York Medical College Division of Oncology, Valhalla, New York, United States
🇺🇸Liberty Hematology and Oncology, Columbia, South Carolina, United States
Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.
- Conditions
- Interventions
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2015-02-12
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 344
- Registration Number
- NCT00419263
- Locations
- 🇨🇦
Manna Research, Toronto, Ontario, Canada
🇺🇸Primary Physicians Research, Inc, Pittsburgh, Pennsylvania, United States
🇺🇸Baylor Clinic-Baylor College of Medicine, Houston, Texas, United States
Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT00289549
- Locations
- 🇺🇸
MD Anderson Cancer Center, University of Texas, Houston, Texas, United States
Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00289562
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
- Conditions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- BioCryst Pharmaceuticals
- Registration Number
- NCT00098332
- Locations
- 🇺🇸
Duke Comprehensive Cancer Center, Durham, North Carolina, United States
🇺🇸M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸Lurleen Wallace Comprehensive Cancer at University of Alabama-Birmingham, Birmingham, Alabama, United States
Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia
- Conditions
- First Posted Date
- 2004-11-04
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT00095381
- Locations
- 🇺🇸
Weil Medical College of Cornell University, New York, New York, United States
BCX-1777 in Treating Patients With Refractory Cancer
- Conditions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- BioCryst Pharmaceuticals
- Registration Number
- NCT00073944
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States